Woman Holding Child

Investors

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Profile

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Press Releases
  • Dec 20, 2021
    SAN DIEGO , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced regulatory updates for its lead drug candidate, repotrectinib, a ROS1/TRK
  • Nov 10, 2021
    SAN DIEGO , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis , M.D., will participate in the
  • Nov 09, 2021
    Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC Conference Multiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and Elzovantinib Cash, Cash Equivalents, and Marketable Securities of $1.0 Billion